Recommended

Register now: Enhancing biopharma workflows with the power of UV/Vis spectroscopy webinar
Download our brand new eBook: A practical guide to single-use filtration in biopharma.
Join us as we look at how the outsourcing of buffers is helping biopharma drug manufacturers to streamline their processes.
Discover more on how Polpharma API meets evolving regulatory guidance around N-nitrosamines control in APIs with Waters’ high-performance analysis instruments.
Learn more about leveraging real-world data, the practical applications of AI and adopting configurable LC/NC solutions.
Download this compendium to discover how hot-melt extrusion can help to overcome pharmaceutical formulation challenges

List view / Grid view

Issue 6 2012

 

Pills
Pills
article

Intelligent Process Condition Monitoring for industrial tablet coating operation

18 December 2012 | By Jun Huang, Saly Romero-Torres, Liam Ryan and Mojgan Moshgbar, Pfizer Inc

This paper presents a feasibility study to develop an Intelligent Process Condition Monitoring (IPCM) system for providing a real time ‘health check’ for the tablet coating process in drug product manufacturing. The study fits well under the framework of Intelligent based Manufacturing (IbM) initiated at Pfizer, and intends to move…

Cancer Research UK drug launched in its first clinical trial
Cancer Research UK drug launched in its first clinical trial
article

Future trends in drug discovery technology

18 December 2012 | By Terry McCann, TJM Consultancy

The average cost to a major pharmaceutical company of developing a new drug is over USD 6 billion1. Herper1 observes that the pharmaceutical industry is gripped by rising failure rates and costs, and suggests that the cost of new drugs will be reduced by new technologies and deeper understanding of…

Drug Discovery and Development
Drug Discovery and Development
article

A new vision of drug discovery and development

18 December 2012 | By D. Lansing Taylor, Director, University of Pittsburgh Drug Discovery Institute and Allegheny Foundation Professor of Computational and Systems Biology, University of Pittsburgh School of Medicine

The pharmaceutical industry has experienced a decade of turbulence driven by the ‘patent cliff’ as major revenue generators are lost to generic status, coupled to the absence of a sustainable pipeline of drug candidates in development that have a good chance of being approved and launched. It is generally agreed…

Figure 1: Sample preparation techniques for mass spectrometry based pharmaceutical and metabolite analysis. The three approaches discussed in the paper are outlined: (Top) mass spectrometry imaging from dosed tissue sections, (Middle) liquid chromatography mass spectrometry of tissue extracts or plasma/serum samples, (Bottom) gas chromatography mass spectrometry of plasma/serum samples
Figure 1: Sample preparation techniques for mass spectrometry based pharmaceutical and metabolite analysis. The three approaches discussed in the paper are outlined: (Top) mass spectrometry imaging from dosed tissue sections, (Middle) liquid chromatography mass spectrometry of tissue extracts or plasma/serum samples, (Bottom) gas chromatography mass spectrometry of plasma/serum samples
article

MS-based methods for detection, quantitation and localisation of pharmaceuticals and metabolites in biological samples

18 December 2012 | By Tyler Greer, Department of Chemistry, University of Wisconsin-Madison and Lingjun Li, Department of Chemistry & School of Pharmacy, University of Wisconsin-Madison

Mass spectrometry is a powerful, multi-faceted technique capable of analysing pharmaceuticals and their metabolites in biological matrices. Although it is more commonly applied to proteins, peptides and lipids, an increasing number of studies use mass spectrometry based techniques to detect, quantitate and localise pharmaceuticals and their metabolites. The availability of…

article

Found in translation

18 December 2012 | By Theresa LaVallee, Senior Director, Translational Medicine Oncology, MedImmune

The development of biologic therapies has significantly shifted the treatment paradigm in medicine, particularly in oncology. Groundbreaking research over the past 20 years has sparked new ways of thinking about disease pathology and opened the door for novel targeted therapies that have truly revolutionised medical care. In more recent years,…

RNAi_Europe
RNAi_Europe
article

Putting the ‘fun’ into functional genomics: a review of RNAi genomewide cellular screens

18 December 2012 | By Dr. Stephen Brown, Sheffield RNAi Screening Facility, Biomedical Sciences, University of Sheffield

As RNA interference (RNAi) enters its teenage years from the first critical observations, it has now reached a multi-billion pound industry. There are few research areas that have expanded as quickly and spectacularly as the field of RNAi. The potential of RNAi initially sparked a functional genomics gold rush. Different…

What is label-free screening and why use it in drug discovery?
What is label-free screening and why use it in drug discovery?
article

What is label-free screening and why use it in drug discovery?

18 December 2012 | By Matthew A. Cooper and Reena Halai, Institute for Molecular Bioscience, the University of Queensland

In the journey of a molecule from its origins in a compound library to candidate drug status, a large variety of profiling must occur to define activity, selectivity, potency, adverse effects, pharmacology and in vivo efficacy. Advances in biophysical methods that can analyse drug interactions with a molecular target, a…

Drug discovery assays for the histone deacetylase class of enzymes
Drug discovery assays for the histone deacetylase class of enzymes
article

Drug discovery assays for the histone deacetylase class of enzymes

18 December 2012 | By Sheraz Gul and Gesa Witt, European ScreeningPort GmbH

The histone deacetylase (HDAC) class of enzyme are a group of conserved enzymes known for their ability to remove acetyl groups from lysine residues on histone tails. Since aberrant HDAC enzyme expression is observed in various diseases, there is increasing interest in finding small molecules which function as HDAC enzyme…

Table 1: Confounding effects influencing measured RNA levels
Table 1: Confounding effects influencing measured RNA levels
article

RNA quality matters

18 December 2012 | By Mikael Kubista, Jens Björkman, David Svec and Robert Sjöback, TATAA Biocenter

RNA levels can be measured with very high specificity, sensitivity and accuracy with techniques such as real-time quantitative PCR (qPCR), microarray analysis and next generation sequencing. This makes messenger (m) RNAs and potentially microRNAs and other non-coding RNAs popular as biomarkers. But RNA is less stable and more dynamic than…

article

Under the Microscope: John Comer, Sirius Analytical

18 December 2012 | By Helen Bahia, Editor, European Pharmaceutical Review

John Comer, Chief Scientific Officer at Sirius Analytical, discusses particle size analysis and characterisation. Sirius Analytical was founded in 1989 with the goal to become a world-class manufacturer of innovative instrumentation for chemical analysis. Today, Sirius Analytical makes instruments to measure the physicochemical properties of drugs, specifically pKa, logP, solubility…